Short Interest in Harvard Bioscience, Inc. (NASDAQ:HBIO) Increases By 34.6%

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 585,089 shares, a growth of 34.6% from the January 15th total of 434,784 shares. Based on an average daily volume of 295,407 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.6% of the shares of the company are short sold. Currently, 1.6% of the shares of the company are short sold. Based on an average daily volume of 295,407 shares, the days-to-cover ratio is presently 2.0 days.

Institutional Trading of Harvard Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its holdings in Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 11,948 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Harvard Bioscience by 7.8% during the first quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock worth $606,000 after acquiring an additional 78,276 shares during the last quarter. Strs Ohio purchased a new position in Harvard Bioscience during the first quarter valued at $117,000. Pasadena Private Wealth LLC grew its stake in Harvard Bioscience by 23.2% during the second quarter. Pasadena Private Wealth LLC now owns 243,911 shares of the medical instruments supplier’s stock valued at $108,000 after acquiring an additional 45,872 shares in the last quarter. Finally, AMH Equity Ltd increased its holdings in Harvard Bioscience by 3.6% in the 2nd quarter. AMH Equity Ltd now owns 3,508,703 shares of the medical instruments supplier’s stock valued at $1,557,000 after acquiring an additional 121,348 shares during the last quarter. Institutional investors own 80.87% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Harvard Bioscience in a report on Monday, December 29th. Wall Street Zen upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a research report on Monday, November 17th. Finally, Zacks Research raised shares of Harvard Bioscience to a “hold” rating in a research report on Thursday, December 11th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $2.00.

Harvard Bioscience Trading Down 1.0%

Harvard Bioscience stock traded down $0.01 during mid-day trading on Friday, hitting $0.55. The stock had a trading volume of 209,943 shares, compared to its average volume of 526,486. Harvard Bioscience has a one year low of $0.28 and a one year high of $1.43. The firm has a market capitalization of $24.80 million, a P/E ratio of -0.45 and a beta of 1.55. The firm’s 50 day moving average is $0.63 and its 200 day moving average is $0.56.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.